England’s National Health Service (NHS) says that it has saved £110 million (US $134 million) by implementing its policy to use the best-value adalimumab after the brand-name Humira lost European patent protection in October 2018.
England’s National Health Service (NHS) says that it has saved £110 million (US $134 million) by implementing its policy to use the best-value adalimumab after the brand-name Humira lost European patent protection in October 2018.
Prior to its loss of patent protection, AbbVie’s Humira was the single medicine on which NHS hospitals spent the most, at £400 million (US $487 million) each year. In preparation for biosimilar availability, the NHS used an approach in which it awarded lots of the adalimumab market to multiple adalimumab manufacturers, and the size of each lot was dependent upon the strength of the offers that drug makers made during the tendering process. The biosimilars now available under the NHS system are Amgen’s Amgevita, Samsung Bioepis’ Imraldi, Sandoz’s Hyrimoz, and Mylan’s Hulio.
The newly announced savings from biosimilar adalimumab come in addition to the £413 million (US $503 million) saved over the past 2 years through the NHS’ concerted efforts to use generics and biosimilars, and the NHS says that it will also “accelerate and widen the uptake of best value biologic medicines” in an effort to save another £400 million to £500 million (US $487 million to $609 million) per year by 2020-2021.
Among the other savings generated during 2018-2019 are £32 million (US $39 million) from biosimilar infliximab, £36 million (US $44 million) from biosimilar etanercept, £45 million (US $55 million) from biosimilar rituximab, and £24 million (US $29 million) from biosimilar trastuzumab.
These savings will be reinvested in new, innovative treatments, says the NHS, noting that “These benefits have only been possible by working closely with patients, clinical teams and NHS trusts.”
Simon Stevens, the NHS’ chief executive, said in a statement that “Use of the best value versions of expensive medicines is already delivering effective treatment for patients across the NHS, including those with cancer, offering the right care for patients while saving the tax payer hundreds of millions of pounds.”
Budget Impact Analysis of Biosimilar Natalizumab in the US
Projected savings from biosimilar natalizumab were $452,611 over 3 years, driven by decreased drug acquisition costs and a utilization shift from reference to biosimilar natalizumab.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Biosimilars Policy Roundup for April 2024—Podcast Edition
May 5th 2024On this episode of Not So Different, The Center for Biosimilars® glances back at all the major biosimilar policy updates from April, including 2 FDA approvals, 1 European approval, and several insights into possible policy changes from the Festival of Biologics USA conference.
Hesitancy in MENA Nations to Adopt WHO Biosimilar Guidelines Hinders Market Development
July 17th 2024The World Health Organization’s (WHO) new guidelines for biosimilar approvals aim to save time and money for manufacturers in the Middle East and North Africa (MENA), but hesitancy among nations to adopt the guidelines is stifling market development of biosimilars.
BioRationality: Time to Get Rid of PBMs if Biosimilars Are to Succeed
July 15th 2024Sarfaraz K. Niazi, PhD, discusses the challenges with pharmacy benefit managers (PBMs) that plague the biosimilar industry and new legislation that attempts to reform their practices and encourage biosimilar adoption.